Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Injections 13pembrolizumab 10tislelizumab 9toripalimab 6atezolizumab 4Nivolumab 4Carboplatin 3trastuzumab deruxtecan 2olaparib 2lenvatinib 2Pemetrexed 2Paclitaxel 2Oxaliplatin 2Gemcitabine 2Fluorouracil 2Docetaxel 2Cyclophosphamide 2Cisplatin 2Cetuximab 2Bevacizumab 2zimberelimab 1talazoparib 1spartalizumab 1sotorasib 1serabelisib 1penpulimab 1niraparib 1nedaplatin 1mirdametinib 1fludarabine phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Tumor × crenigacestat × 1 year × Clear all
NCT02836600 2025-08-07

A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
11 enrolled 9 charts
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡